Biovica International AB (OSTO:BIOVIC B) Interest Expense : kr-0.92 Mil (TTM As of Apr. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biovica International AB's interest expense for the three months ended in Apr. 2025 was kr -0.25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Apr. 2025 was kr-0.92 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biovica International AB's Operating Income for the three months ended in Apr. 2025 was kr -21.27 Mil. Biovica International AB's Interest Expense for the three months ended in Apr. 2025 was kr -0.25 Mil. Biovica International AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biovica International AB Interest Expense Historical Data

The historical data trend for Biovica International AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Interest Expense Chart

Biovica International AB Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

Interest Expense

Get a 7-Day Free Trial

-0.06

-0.08

-0.28

-0.29

-0.22

Biovica International AB Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25
Interest Expense	Get a 7-Day Free Trial															-0.07	-0.82	0.07	0.08	-0.25

Biovica International AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Apr. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.92 Mil.

Biovica International AB (OSTO:BIOVIC B) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biovica International AB's Interest Expense for the three months ended in Apr. 2025 was kr-0.25 Mil. Its Operating Income for the three months ended in Apr. 2025 was kr-21.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Apr. 2025 was kr1.74 Mil.

Biovica International AB's Interest Coverage for the quarter that ended in Apr. 2025 is calculated as

Biovica International AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Biovica International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

9II:Germany

Address

Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37

Website

https://www.biovica.com

Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines